Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACHROMYCIN vs OXERVATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.
Infections caused by susceptible strains of bacteria (e.g., Mycoplasma pneumoniae, Chlamydia trachomatis, Rickettsia species),Acne vulgaris,Periodontitis (as adjunctive therapy),Off-label: Chronic obstructive pulmonary disease exacerbations, malaria prophylaxis
Treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have adequate blood supply,Off-label: Treatment of pressure ulcers, venous stasis ulcers
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
1 drop in the affected eye(s) twice daily, approximately 6 hours apart.
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life of Cenegermin is approximately 12 hours following topical ocular administration, supporting once-daily dosing
Primarily renally excreted unchanged; minimal hepatic metabolism.
Becaplermin is a protein that is expected to be degraded into small peptides and amino acids via general protein catabolism; specific hepatic metabolism is not a significant pathway.
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Primarily renal elimination of the active metabolite (Cenegermin) as small peptides and amino acids; unchanged drug excretion is negligible
50-60% bound to serum proteins
Cenegermin binding to plasma proteins is minimal (<10%) due to its small protein nature
1.5-2.0 L/kg; indicates extensive tissue penetration
Vd not determined for topical ocular route; systemic exposure is low, with Vd estimated less than 0.1 L/kg based on limited systemic absorption
Oral: 75-80%; Topical: minimal systemic absorption
Topical ocular: Systemic bioavailability is negligible (<1%) due to low corneal penetration and extensive proteolysis at the ocular surface
GFR 50-80 m L/min: no adjustment; GFR 10-50 m L/min: administer every 12-24 hours; GFR <10 m L/min: administer every 24 hours or avoid.
No dose adjustment required for renal impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No dose adjustment required for hepatic impairment.
25-50 mg/kg/day orally divided every 6 hours; maximum 2 g/day.
Safety and efficacy in pediatric patients have not been established.
Initiate at lower end of dosing range due to age-related renal function decline; monitor renal function.
No specific dose adjustment required; use same dosing as adults.
No FDA boxed warning
OXERVATE has been associated with an increased risk of mortality from secondary malignancies in patients who have had a malignant neoplasm. The drug should not be used in patients with active malignancy.
Photosensitivity reactions,Esophageal ulceration if taken with insufficient fluids,Pseudotumor cerebri in adults,Pancreatitis,Hepatotoxicity,Renal impairment (accumulation may worsen renal function),Superinfection with resistant organisms
Increased risk of malignancy in patients with a history of malignancy; application to ulcers with malignant cells may promote tumor growth; use only on clean, non-infected ulcers; monitor for signs of infection; avoid application to wounds with exposed bone, tendon, or joint capsule.
Hypersensitivity to tetracyclines,Pregnancy (second and third trimesters) due to fetal harm,Children under 8 years due to permanent tooth discoloration and enamel hypoplasia,Severe hepatic or renal impairment
Known hypersensitivity to becaplermin or any product component; active neoplasm at the application site; patients with a history of malignancy (relative contraindication based on black box warning).
Avoid dairy products (milk, cheese, yogurt) within 2-3 hours of taking Achromycin, as calcium binds tetracycline and reduces absorption. Also avoid iron-fortified foods, calcium-fortified juices, and high-calcium meals. Take on an empty stomach with a full glass of water; food, especially dairy, decreases absorption by up to 50%.
None known; no significant food interactions reported.
ACHROMYCIN (tetracycline) is classified as FDA Pregnancy Category D. First trimester: Associated with minor malformations, but risk is low. Second and third trimesters: Exposure can cause permanent discoloration of deciduous teeth (yellow-gray-brown) due to deposition during calcification, and reversible inhibition of bone growth. Avoid use after the fourth month of pregnancy. Risk of maternal hepatotoxicity if used intravenously in pregnancy.
OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducted. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: unknown risk; second and third trimesters: unknown risk.
Tetracycline is excreted into breast milk in low concentrations. Theoretical risk of dental discoloration and bone growth suppression in nursing infants, but levels are usually below therapeutic. M/P ratio is approximately 0.5-0.8. Use with caution, especially in infants with prolonged exposure. American Academy of Pediatrics considers tetracyclines compatible with breastfeeding.
No data on presence in human milk, effects on breastfed infant, or milk production. Caution advised; M/P ratio unknown.
No dosage adjustment is recommended for pregnancy; however, use is contraindicated after the first trimester due to risks to the fetus. If essential, use the lowest effective dose for the shortest duration. Intravenous doses should be cautious due to risk of hepatotoxicity; reduce dose in renal impairment.
No pharmacokinetic studies in pregnancy; dose adjustments not established. Use standard dosing with caution.
Achromycin (tetracycline) should be administered on an empty stomach (1 hour before or 2 hours after meals) to ensure adequate absorption. Avoid concurrent use with dairy products, antacids, iron, calcium, magnesium, or bismuth subsalicylate as they chelate tetracycline and reduce absorption. Tetracycline can cause photosensitivity; advise patients to avoid prolonged sun exposure and use sunscreen. It is contraindicated in pregnancy (risk of hepatotoxicity and fetal bone/teeth discoloration), lactation, and children under 8 years (permanent tooth discoloration and bone growth inhibition). Monitor for signs of superinfection, especially Clostridium difficile-associated diarrhea. Tetracycline may increase the effect of warfarin; monitor INR closely.
OXERVATE (cenegermin-bkbj) is a recombinant human nerve growth factor for neurotrophic keratitis. Administer as one drop in the affected eye(s) six times daily at 2-hour intervals for 8 weeks. Refrigerate at 2-8°C; do not freeze. Protect from light. Discard unused drops after 1 week of first opening. Monitor for corneal epithelial defect closure. Use with caution in patients with active ocular infections or inflammation.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Do not take with dairy products, antacids, iron supplements, or calcium supplements; separate by at least 2-3 hours.,Avoid excessive sunlight or tanning beds; use sunscreen and wear protective clothing to prevent severe sunburn.,Complete the full course of treatment even if you feel better; do not skip doses.,Notify your doctor immediately if you develop watery or bloody diarrhea, rash, headache, blurred vision, or signs of infection worsening.,Do not use if you are pregnant, planning to become pregnant, or breastfeeding; this medication can harm the unborn baby or nursing infant.,Keep out of reach of children; expired tetracycline can cause kidney damage.
Wash hands before each use.,Instill one drop in the affected eye(s) every 2 hours, 6 times daily.,Refrigerate the medication at all times; do not freeze.,Use within 1 week after opening the vial.,Avoid touching the dropper tip to any surface.,Do not use contact lenses during treatment.,Report any eye pain, redness, or vision changes immediately.,Complete the full 8-week course even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACHROMYCIN vs OXERVATE, answered by our medical review team.
ACHROMYCIN is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. OXERVATE is a Growth Factor (Ophthalmic) that works by OXERVATE (becaplermin) is a recombinant human platelet-derived growth factor (rh PDGF-BB) that promotes wound healing by stimulating chemotaxis and mitogenesis of fibroblasts, smooth muscle cells, and other cells involved in tissue repair.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACHROMYCIN and OXERVATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACHROMYCIN is: 250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.. The standard adult dose of OXERVATE is: 1 drop in the affected eye(s) twice daily, approximately 6 hours apart.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACHROMYCIN and OXERVATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACHROMYCIN is classified as Category C. ACHROMYCIN (tetracycline) is classified as FDA Pregnancy Category D. First trimester: Associated with minor malformations, but risk is low. Second and third trimesters: Exposure ca. OXERVATE is classified as Category C. OXERVATE contains cenegermin, a recombinant human nerve growth factor. No adequate and well-controlled studies in pregnant women. Animal reproductive studies have not been conducte. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.